TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

Hepatitis B Clinical Trial

— BOOST-9  

Official title:

Augmentation of Humoral Immunity Using Toll-Like Receptor (TLR) 9 Adjuvanted HBV Surface Antigen to Enhance Anti-HBSAg Response

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04843852
• Other study ID #: HP-00095866
• Status: Withdrawn
• Phase: Phase 1
• Start date: July 2022
• Est. completion date: July 2024

Study information

• Verified date: July 2022
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Unmethylated cystine-guanosine dinucleotide (CpG) motifs are pathogen-associated molecular patterns (PAMPs) associated with bacterial and viral-derived DNA that activate the innate and humoral immunity via toll-like receptor 9. This is a randomized controlled pilot study evaluating the clinical and immune correlates of a seroprotective immune response against a CpG-adjuvanted vaccine for hepatitis B.

Description:

This is an open-label, randomized, pilot study to assess the effect of CpG-adjuvanted vaccination among people with chronic hepatitis B. This study will evaluate the effect of CpG-adjuvanted vaccination on B-cells that produce anti-HBsAg antibody.

The primary hypothesis is that TLR9 agonism with CpG-adjuvanted hepatitis B vaccine will increase the number of anti-HBsAg producing B-cells in people with chronic hepatitis B infection who are virally suppressed on nucleos(t)ide analogue (NUC) therapy.

In this study, 40 people with chronic hepatitis B virally suppressed on NUC therapy will be randomized in a 1:1 fashion to receive an 0.5ml intramuscular injection of HEPLISAV-B vaccine

• an FDA approved vaccine for preventing hepatitis B infection. Participants randomized to receive the vaccine will receive a total of 2 injections, at day 0 and week 4. Participants will be evaluated at days 7, 14, 28, 35, 56, 96, 393 for adverse events, with and blood sample collections on days 0, 14, 28, 56, 196.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

In order to participate in this study, an individual must meet all the following criteria:

1. >18 years old

2. Diagnosed with CHB infection, without HIV, hepatitis C nor hepatitis D co-infections

3. Currently receiving OAV with HBV VL <100 IU/ml for = 12 months

4. Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures.

5. Determined by medical history, targeted physical examination, and clinical judgement of the investigator to be in good health.

CHB infection is defined as any individual with documentation of the following in the past:

• Positive HBsAg and/or detectable HBV DNA test

Exclusion Criteria:

A participant will be ineligible to participate on this study if any of the following criteria are met:

1. Pregnancy or breast feeding.

2. Received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to Day 1.

3. Received or plans to receive live virus vaccines within 4 weeks, and inactivated vaccine within 2 weeks prior to randomization; or plans to receive a non-study vaccine within 28 days after any dose of study vaccine (with exception for seasonal influenza vaccine within 14 days of study vaccine).

4. Administration of any blood products within 3 months prior to randomization.

5. Participation in a study with an investigational study product or device within 30 days of randomization.

6. Has allergies to any hepatitis B and/or yeast-based vaccines.

7. Subjects meeting any of the following laboratory parameters at screening:

1. ALT greater than 3 times the upper limit of normal

2. Elevated total bilirubin WITH direct bilirubin greater than 2 times upper limit of normal

8. Is acutely ill or febrile 72 hours prior to or at vaccine dosing (fever defined as = 38.0°C/100.4°F). Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.

9. Have any chronic or acute or unstable conditions that the investigator considers a contraindication to study participation.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B

Intervention

Drug:
• Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
one 0.5ml intramuscular injection on day 0 and week 4.

Locations

Country	Name	City	State
United States	Institute of Human Virology, University of Maryland School of Medicine	Baltimore	Maryland
United States	Dr Sang V Tran Internal Medicine Practice	Falls Church	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Hepatitis B surface antigen-specific antibodies	Change in hepatitis B surface antigen-specific antibody (anti-HBsAg)-producing B-cells	baseline to day 56
Other	Anti-HBsAg Seroconversion	Number of patients with anti-HBsAg seroconversion	Day 0 through 12 months post vaccination
Primary	Safety and reactogenicity of the Hepatitis B Virus Surface Antigen, Recombinant (HEPLISAV-B; Dynavax Technologies Corporation) Vaccine in patients with chronic hepatitis B	Occurrence of local and systemic solicited adverse events	Baseline to 7 days following each vaccine dose
Primary	Occurrence of unsolicited adverse events	Unsolicited adverse events	from dose 1 to 28 days following each vaccine dose
Primary	Medically Attended Adverse Events	Occurrence of Medically Attended Adverse Events (MAAEs)	From first vaccine to 12 months after last vaccine on study.